Studying baxdrostat with imaging for primary aldosteronism
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests whether a new pill called baxdrostat can help reduce the activity of aldosterone-producing nodules in the adrenal glands. It uses special imaging to see if the treatment shrinks or changes these nodules, which might help control blood pressure better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have been diagnosed with primary aldosteronism (a condition where the adrenal glands make too much aldosterone).
- You must have at least one adrenal nodule (a small growth on the adrenal gland) that is between 0.5 and 2.5 cm, seen on a CT or MRI scan.
- Your kidney function must be reasonably good (checked with a blood test).
- You must be willing to take a daily study pill (baxdrostat) for 6 months and attend study visits.
- You must be willing to have a PET-CT scan (an imaging test) as part of the study.
- You cannot be pregnant or breastfeeding, and if you could become pregnant, you must have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, SAL0140, for people with primary aldosteronism, a condition where the adrenal glands make too much aldosterone, causing high blood pressure. The study aims to see if the drug can lower blood pressure and improve health.
This trial tests a new imaging method called [18F]CETO PET scan to better understand the cause of high blood pressure due to primary aldosteronism (PA). It may help guide treatment decisions without needing more invasive tests.
This study looks at how primary aldosteronism affects the heart and blood vessels, and whether blocking its hormone signal (with spironolactone or eplerenone) changes those findings on imaging tests. It is small and focuses on people with confirmed or suspected primary aldosteronism who are being followed for heart health.
This trial tests a special PET scan that may help doctors find the exact cause of high blood pressure related to an adrenal gland problem. It could help decide if surgery or medicine is the best treatment for you.
This trial tests whether a treatment called SAAE can improve “ventricular remodeling,” meaning changes in the heart muscle, in people with primary aldosteronism (PA). It may help the heart work more efficiently by targeting the cause of high aldosterone levels.
This study tests a new drug called QLS1410 for people with primary aldosteronism, a condition that causes high blood pressure due to too much aldosterone. The drug aims to lower blood pressure and improve health, potentially offering a new treatment option.
Hear when a new Primary Aldosteronism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.